SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-036770
Filing Date
2023-08-02
Accepted
2023-08-02 07:05:42
Documents
14
Period of Report
2023-08-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20230802.htm   iXBRL 8-K 53504
2 EX-99.1 eypt-ex99_1.htm EX-99.1 332134
3 GRAPHIC img96707757_0.jpg GRAPHIC 5406
  Complete submission text file 0000950170-23-036770.txt   523163

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eypt-20230802_lab.xml EX-101.LAB 12806
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eypt-20230802.xsd EX-101.SCH 2475
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eypt-20230802_pre.xml EX-101.PRE 9457
8 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20230802_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 231133699
SIC: 3826 Laboratory Analytical Instruments